1. Home
  2. BMRA vs BIAF Comparison

BMRA vs BIAF Comparison

Compare BMRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

HOLD

Current Price

$1.62

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

SELL

Current Price

$5.84

Market Cap

4.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BMRA
BIAF
Founded
1971
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.5M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
BMRA
BIAF
Price
$1.62
$5.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.0K
1.9M
Earning Date
04-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,311,000.00
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$1.45
$0.23
52 Week High
$3.42
$13.50

Technical Indicators

Market Signals
Indicator
BMRA
BIAF
Relative Strength Index (RSI) 52.17 89.55
Support Level N/A $0.96
Resistance Level $1.68 N/A
Average True Range (ATR) 0.05 0.11
MACD 0.01 0.36
Stochastic Oscillator 77.78 91.53

Price Performance

Historical Comparison
BMRA
BIAF

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: